Clinical Trial Update: Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning [Phase 4]

View source ↗

Summary

Phase 4 study evaluating neurocognitive and emotional functioning after switching from AtriPla to Eviplera in people with HIV-associated neurocognitive disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Neurocognitive Disorder
• Neurocognitive Decline

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• Eviplera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: UMC Utrecht | Conditions: Neurocognitive Decline, HIV Associated Neurocognitive Disorder | Phase 4 | Status: COMPLETED